Skip to content

Clinical trials

Hematologic Diseases trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hematologic Diseases Country / region: United States Clear all

297 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200011
20015
20021
20035
20047
20058
20066
20077
20087
200912
201013
201111
20129
20139
201413
20159
20167
201720
201812
201911
202020
202117
202217
20236
202411
202510
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed156
Terminated47
Recruiting34
Active, not recruiting25
Withdrawn11
Unknown status9
Enrolling by invitation8
No longer available4
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Seagen Inc.30
M.D. Anderson Cancer Center14
National Heart, Lung, and Blood Institute (NHLBI)13
Emory University7
Fairview University Medical Center6
Novartis Pharmaceuticals6
Pfizer6
Vertex Pharmaceuticals Incorporated6
BioMarin Pharmaceutical5
Loxo Oncology, Inc.5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hematologic Diseases297
Leukemia42
Neoplasms42
Lymphoma37
Anemia, Sickle Cell36
Genetic Diseases, Inborn33
Leukemia, Myeloid, Acute30
Multiple Myeloma30
Myelodysplastic Syndromes30
Immune System Diseases29

Trials

Showing 1 to 25 of 297. Each trial links to its page on Pharma Observatory.

197 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.